Abstract:Abstract Background Sublobar resection is a potential alternative to lobectomy for elderly patients with early-stage non-small-cell lung cancer, with better short term outcomes and similar oncological outcomes. We aimed to compare sublobar resection and lobectomy in patients with clinical stage T1N0M0 non-small-cell lung cancer aged 70 years or older. Methods We did this prospective, open label, randomised, controlled, multicentre, non-inferiority, phase 3 trial (STEPS; registered with the Chinese Thoracic Oncology Group, number CTON1504) comparing sublobar resection and lobectomy for treatment of elderly patients with early-stage non-small-cell lung cancer. Patients were aged 70 years or older, with preoperative thoracic CT showing suspected peripheral non-small-cell lung cancer, clinical stage IA, consolidation to maximum tumour diameter ratio of 0·5 or higher, and were eligible for sublobar resection with sufficient margin. Intraoperative eligibility criteria included histologically confirmed invasive non-small-cell lung cancer, pathological exclusion of suspected lymph node involvement, and feasibility of sublobar resection in terms of surgical margin requirement. Patients gave informed consent, completed 4-year mortality index and comprehensive geriatric assessment if necessary, and had both forced expiratory volume in 1 s and diffusing capacity of the lungs for carbon monoxide of 50% or more in pulmonary function tests. Patients were excluded if they had a previous history of thoracic surgery and malignant tumour history within the past 5 years. We expect a total of 339 patients to be randomly assigned to the two treatment groups and participants will be followed-up every 6 months for 3 years. The primary outcome is 3-year disease-free survival (with a non-inferiority margin of 15%). The study will develop in accordance to the Declaration of Helsinki. Ethical Committee approval (Peking University Institutional Review Board) was obtained on Oct 30, 2014, before registration (reference number IRB00001052-13053). This trial is registered with ClinicalTrials, number NCT02360761. Findings As of Jan 29, 2016, 66 patients have been registered to the study; the accrual is slower than anticipated. One patient receiving sublobar resection died of a surgical complication. Interpretation To our knowledge, the present study is the only prospective, multicentre, randomised, controlled trial to compare sublobar resection and lobectomy for elderly patients (≥70 years) with early-stage non-small-cell lung cancer. Funding Medtronic Inc.

Sublobar Resection for Adenocarcinoma in Situ and Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019): a Study Protocol of Prospective, Single-Arm, Multicenter, Phase III Study

Regional Versus Extended Lymph Node Dissection for Intrahepatic Cholangiocarcinoma: a Randomized Controlled Trial Protocol

Effectiveness and Safety of Systematic and Selective Lymphadenectomies in Chinese Patients with Non-Small Cell Lung Cancer Who Received Sublobar Resection.

Sublobar Resection Is Associated With Better Perioperative Outcomes In Elderly Patients With Clinical Stage I Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study

Sub-lobar resection versus lobectomy for challenging intraoperative frozen sections in lung adenocarcinoma within 3 cm

Surgery for Pre- and Minimally Invasive Lung Adenocarcinoma.

Safety and Effectiveness of Neoadjuvant Immunotherapy Combined with Chemotherapy Followed by Surgical Resection in Patients with Stage I-IIIA Small-Cell Lung Cancer: a Retrospective Single-Arm Clinical Trial.

Sublobar Resections for Small-Sized Stage Ia Lung Adenocarcinoma: a Sino-Japanese Multicenter Study

Protocol for a Single-Arm, Multicenter, Prospective, Confirmatory Phase III Trial of Wedge Resection for Invasive Ground Glass Opacity-Featured Lung Cancer with a Size ≤2 Cm and a Consolidation Tumor Ratio Between 0.25 and 0.5 (ECTOP-1020 Study)

Segmentectomy for ground glass-dominant invasive lung cancer with tumour diameter of 2-3 cm: protocol for a single-arm, multicentre, phase III trial (ECTOP1012)

Sublobectomy Versus Lobectomy for Long-Term Survival Outcomes of Early-Stage Non-Small Cell Lung Cancer with a Tumor Size ≤2 Cm Accompanied by Visceral Pleural Invasion: a SEER Population-Based Study

Prediction of the Pathological Subtypes by Intraoperative Frozen Section for Patients with Ct1n0m0 Invasive Lung Adenocarcinoma (ECTOP-1015): a Prospective Multi-Center Study

Prognostic Impact of Lymphadenectomy on Outcomes of Sublobar Resection for Stage IA Non–small Cell Lung Cancer ≤2 Cm

Real-world Surgical Treatment Patterns and Clinical Outcomes in Patients with Stages IA–IIIA Non-Small Cell Lung Cancer: a Retrospective Multicentric Observational Study Involving 11,958 Patients

Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708, SURPRISE)

Sublobar resection versus lobectomy in Surgical Treatment of Elderly Patients with early-stage non-small cell lung cancer (STEPS): study protocol for a randomized controlled trial

[Current Situation and Confusion of Sublobar Resection for Early Stage Lung Cancer].

Comparison of thoracoabdominal versus abdominal-transhiatal surgical approaches in Siewert type II adenocarcinoma at the esophagogastric junction: Protocol for a prospective multicenter randomized controlled trial

Excellent Prognosis of Patients With Invasive Lung Adenocarcinomas During Surgery Misdiagnosed as Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, or Minimally Invasive Adenocarcinoma by Frozen Section

Comparison between sublobar resection and lobectomy for the surgical treatment of elderly patients with early stage non-small-cell lung cancer (STEPS): an open label, multicentre, non-inferiority, randomised, phase 3 clinical trial

Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy